Microsoft’s BrainHealth app is testing a new brain death inhibitor that could eventually become standard in hospitals.
The company is testing two new compounds to fight a rare form of brain damage called encephalopathy (aka encephalitis) that can lead to severe brain damage.
BrainHealth was created by Microsoft’s neuroscientists at Johns Hopkins University in Maryland, who also worked on the Microsoft’s Xbox One video game console and Microsoft Surface.
It has also worked with the University of California, San Francisco to develop a drug for treating the disorder.
While Microsoft says the drugs are designed to prevent encephalopathies in patients who are suffering from Alzheimer’s disease, it is also testing a second compound, called DMX, which was designed to treat encephalopathic conditions such as Parkinson’s disease.DMX has a half-life of about 10 days, so it is likely to work against patients with milder forms of the disease.
The new drugs are being tested in two different types of patients.
In a clinical trial, patients are given two doses of DMX and are monitored for about three weeks.
In the trial, researchers are also looking at the drug in a large group of healthy volunteers.
Both DMX compounds are similar to those found in Microsoft’s own product, the Xbox One, which has been one of the best-selling video game consoles in the world.
In addition to being able to help fight encephalitic encephalomyelitis, the drug is also being tested to treat conditions such a heart attack and stroke.
“We know that our product is safe and effective, and the safety and efficacy of this product is being tested by a large, large group, with a large number of people, in a variety of clinical trials,” Microsoft’s chief medical officer, Joe Belfiore, told reporters on a conference call.
“It’s important that we don’t confuse that with anything else.”
The drug has been tested in healthy volunteers for six months and in patients with severe brain injury, with similar results, Belfiores said.
“In patients with the brain injury that we’re talking about, we’re seeing that this drug can really help with brain injury,” he said.
Belfiore also said the drug could be used to treat people with a rare and aggressive form of the condition known as encephalomegaly, where the brain has become too large to be removed.
“When people develop encephalomyelitis they are unable to move their limbs or to communicate,” Belfiors said.
The drug, which is already approved by the Food and Drug Administration, is currently only approved to treat the rare condition.
The two new drugs were developed by researchers at the Johns Hopkins lab.
One is called SZDZ4-1, and is a combination of the two drugs.
The other is called DMx, which the researchers say is a new compound to treat a different type of encephalic disorder called DMZ.SZDz4-2, the new compound, is also a mixture of the DMX drug and the DMx drug.
The drug has an estimated half-lives of about nine days, meaning it can work in a patient for a longer period of time.
The DMX compound, the researchers added, has been found to be safe in clinical trials.
However, it has not been tested extensively in humans.
In clinical trials, only about one third of people taking DMX showed signs of brain injury after a few weeks.
The drugs are also being used in the lab to test the effectiveness of a drug called FQV1-6, which improves blood flow to the brain.
FQv1-4 is a compound developed by the Johns Jacobs team at the University, who developed the drug before Belfioros’ company.
“The drug is in clinical trial in the UK, and that drug is approved by Pfizer,” Beliores said, referring to the pharmaceutical company which makes the drug.
“We’ve not been able to get Pfizer to agree to an FDA approval.”
The drugs were designed to stop the bleeding in the brain, which happens when a blood vessel or brain tissue is ruptured.
If the drugs stop the blood flow, the bleeding stops.
The drugs are meant to work in healthy people.
However there are reports that they are also not safe in healthy animals.
In a trial of two people with severe encephaloxic amnesia, the drugs did not help them get out of bed.
They were able to walk again after only five days.
The research also showed that the drugs didn’t stop the progression of brain cancer.
A number of other drugs were tested for their potential as treatments for brain damage in people suffering from milder cases of enceromegalo.
Some of the drugs, including a drug developed by Belfios lab, have been approved for treating Alzheimer’s, Parkinson’s